Karoly Nikolich is Chairman of the Board of Directors and Chief Executive Officer of Alkahest. During the 1980s, he led Genentech’s entry into neuroscience and led and participated in the development of numerous protein therapeutics. He was Vice President of Research at Lynx Therapeutics, co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. He has served as venture partner with Pivotal BioVentures, and has been on the boards and scientific advisory boards at a number of neurotherapeutics and biotech companies, as well. Dr. Nikolich is a graduate of Eotvos University in Budapest and worked as postdoctoral fellow at Tulane University and UCSF before joining Genentech. He has been Adjunct Professor in the Department of Psychiatry at Stanford University Medical School.
Karoly Nikolich
Chairman of the Board of Directors and Chief Executive Officer of Alkahest.
Visit website: https://www.alkahest.com/karoly-nikolich/
See also: Alkahest - Biotechnology company focused on treating neurodegenerative and other age-related diseases
Details last updated 17-Oct-2019
Karoly Nikolich News
Device by Alkahest to treat dialysis-associated dementia
Longevity Technology - 02-Jun-2020
With phase 2 study announced, hopes are up for end-stage renal disease sufferers
Read more...Chronokines in young blood could be the cure for Alzheimer's
New Atlas - 06-Aug-2019
Plasma proteins to the rescue of good-old memories in Alzheimer's
Read more...Young blood does little to reverse Alzheimer’s in first test
Science Magazine - 01-Nov-2017
16 people with mild or moderate Alzheimer’s disease received weekly injections of young plasma. ...
Read more...